Condition
Immunologic Activity Alteration
Total Trials
7
Recruiting
2
Active
2
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results80% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Completed4
Recruiting2
Terminated1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT03928431Not ApplicableRecruiting
Restoration of Microbiota in Neonates
NCT06580639Recruiting
The Role of a Mycobacterium Growth Inhibition Assay to Quantify Host Immune Control of M. Tuberculosis
NCT04768621Not ApplicableCompleted
Health Consequences of Wintering in the French Southern and Antarctic Territories
NCT04354792CompletedPrimary
Asymptomatic COVID-19 Infection Among Healthcare Workers
NCT03134768CompletedPrimary
Effect of Birth on Immunological Parameters in Cord Blood
NCT03796949Completed
Threatened Preterm Birth and Time of Subsequent Delivery -a Prediction Model
NCT01210066Phase 1Terminated
Pain, Opioids and Pro-Inflammatory Immune Responses
Showing all 7 trials